Search research articles
Contact Us
Filters
Showing results (61-70 of 82) with videos related to
Page
of 9
Sort By:
British Journal of Clinical Pharmacology
|
February 19, 2002
Randomized cross-over clinical trial to study potential pharmacokinetic interactions between cisplatin or carboplatin and etoposide
Huw D Thomas, David J Porter, Imke Bartelink, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 10, 2005
A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules
Alan V Boddy, E Ruth Plummer, Radha Todd, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 13, 2016
Pharmacogenetic association of MBL2 and CD95 polymorphisms with grade 3 infection following adjuvant therapy for breast cancer with doxorubicin and cyclophosphamide
David Jamieson, Nicola Sunter, Sara Muro, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 13, 2010
Malnourished Malawian patients presenting with large Wilms tumours have a decreased vincristine clearance rate
Trijn Israels, Carola W N Damen, Michael Cole, et al.
Biochemical Pharmacology
|
October 22, 2011
Therapy-induced carboplatin-DNA adduct levels in human ovarian tumours in relation to assessment of adduct measurement in mouse tissues
Ian W H Jarvis, Emma L Meczes, Huw D Thomas, et al.
Cancer Chemotherapy and Pharmacology
|
May 11, 2004
Pharmacokinetically guided dosing of carboplatin in paediatric cancer patients with bilateral nephrectomy
Gareth J Veal, Martin W English, Richard G Grundy, et al.
Journal of the National Cancer Institute
|
May 8, 2003
2-[11C]thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337
Paula Wells, Eric Aboagye, Roger N Gunn, et al.
Pharmacogenetics and Genomics
|
September 28, 2011
Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy
David Jamieson, Nicola Cresti, Johanne Bray, et al.
JAMA Oncology
|
July 28, 2022
Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration
Natansh D Modi, Ahmad Y Abuhelwa, Ross A McKinnon, et al.
International Journal of Cancer
|
July 17, 2015
High-resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers
Barry M Dent, Laura F Ogle, Rachel L O'Donnell, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 82) with videos related to
Sort By:
Page
of 9
British Journal of Clinical Pharmacology
|
February 19, 2002
Randomized cross-over clinical trial to study potential pharmacokinetic interactions between cisplatin or carboplatin and etoposide
Huw D Thomas, David J Porter, Imke Bartelink, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 10, 2005
A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules
Alan V Boddy, E Ruth Plummer, Radha Todd, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 13, 2016
Pharmacogenetic association of MBL2 and CD95 polymorphisms with grade 3 infection following adjuvant therapy for breast cancer with doxorubicin and cyclophosphamide
David Jamieson, Nicola Sunter, Sara Muro, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 13, 2010
Malnourished Malawian patients presenting with large Wilms tumours have a decreased vincristine clearance rate
Trijn Israels, Carola W N Damen, Michael Cole, et al.
Biochemical Pharmacology
|
October 22, 2011
Therapy-induced carboplatin-DNA adduct levels in human ovarian tumours in relation to assessment of adduct measurement in mouse tissues
Ian W H Jarvis, Emma L Meczes, Huw D Thomas, et al.
Cancer Chemotherapy and Pharmacology
|
May 11, 2004
Pharmacokinetically guided dosing of carboplatin in paediatric cancer patients with bilateral nephrectomy
Gareth J Veal, Martin W English, Richard G Grundy, et al.
Journal of the National Cancer Institute
|
May 8, 2003
2-[11C]thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337
Paula Wells, Eric Aboagye, Roger N Gunn, et al.
Pharmacogenetics and Genomics
|
September 28, 2011
Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy
David Jamieson, Nicola Cresti, Johanne Bray, et al.
JAMA Oncology
|
July 28, 2022
Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration
Natansh D Modi, Ahmad Y Abuhelwa, Ross A McKinnon, et al.
International Journal of Cancer
|
July 17, 2015
High-resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers
Barry M Dent, Laura F Ogle, Rachel L O'Donnell, et al.
Page
of 9